Search research articles
Contact Us
Filters
Showing results (91-100 of 138) with videos related to
Page
of 14
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
April 1, 1997
Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
F I Raynaud, R M Orr, P M Goddard, et al.
Cancer Chemotherapy and Pharmacology
|
November 12, 2010
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
Robin L Jones, David Olmos, Khin Thway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2002
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331
Hugo E R Ford, Fraser Mitchell, David Cunningham, et al.
Cancer Research
|
March 1, 1995
Idoxifene: report of a phase I study in patients with metastatic breast cancer
R C Coombes, B P Haynes, M Dowsett, et al.
Lancet (London, England)
|
October 14, 1989
Intensive treatment of multiple myeloma and criteria for complete remission
M E Gore, P J Selby, C Viner, et al.
International Journal of Cancer
|
November 4, 1996
Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol
H M Coley, M Jarman, N Brooks, et al.
British Journal of Cancer
|
April 7, 1998
Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells
A S Ojugo, P M McSheehy, M Stubbs, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 16, 2005
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
John R Zalcberg, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2006
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Martine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
Clinical Sarcoma Research
|
August 5, 2014
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
Anna Maria Frezza, Charlotte Benson, Ian R Judson, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 138) with videos related to
Sort By:
Page
of 14
The Journal of Pharmacology and Experimental Therapeutics
|
April 1, 1997
Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
F I Raynaud, R M Orr, P M Goddard, et al.
Cancer Chemotherapy and Pharmacology
|
November 12, 2010
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
Robin L Jones, David Olmos, Khin Thway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2002
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331
Hugo E R Ford, Fraser Mitchell, David Cunningham, et al.
Cancer Research
|
March 1, 1995
Idoxifene: report of a phase I study in patients with metastatic breast cancer
R C Coombes, B P Haynes, M Dowsett, et al.
Lancet (London, England)
|
October 14, 1989
Intensive treatment of multiple myeloma and criteria for complete remission
M E Gore, P J Selby, C Viner, et al.
International Journal of Cancer
|
November 4, 1996
Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol
H M Coley, M Jarman, N Brooks, et al.
British Journal of Cancer
|
April 7, 1998
Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells
A S Ojugo, P M McSheehy, M Stubbs, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 16, 2005
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
John R Zalcberg, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2006
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Martine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
Clinical Sarcoma Research
|
August 5, 2014
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
Anna Maria Frezza, Charlotte Benson, Ian R Judson, et al.
Page
of 14